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I. INTRODUCTION 
In April 2011 Scotland abolished the prescription fee (co-
payment) which had applied to all community prescribed 
items. Nicola Sturgeon, then Scottish Health Secretary, had 
described the prescription fee as a ‘tax on ill health.’ Beyond 
reporting on the change in number of items prescribed, no 
evaluation of the policy had been planned or commissioned. 
However, the availability of administrative prescribing and 
hospital admissions data permitted the design and conduct of 




The Community Health Index (CHI) is a unique identifier 
used across Scottish Health Services which permits the 
linking of data from different services. Hospital admissions 
data are recorded in the Scottish Morbidity Records (SMR), 
while community prescribing data are recorded in the 
Prescribing Information System (PIS). Unfortunately, CHI 
was not recorded in the PIS during the whole study period 
(July 2005 – December 2013), limiting this study to a general 
practice level data. 
B. Exposure 
Prior to the fee abolition those in certain age groups or 
with certain conditions were exempt from the fee, permitting 
the identification of intervention and counterfactual cases. 
These groups had to be vulnerable to changes in medication 
adherence and identifiable within SMR and PIS. Those with 
asthma or Chronic Obstructive Pulmonary Disease (COPD) 
taking inhaled corticosteroids were identified as the 
intervention group, while those taking medication for 
diabetes mellitus formed the counterfactual group. 
C. Analysis 
Mixed effects Poisson models were used to analyse the 
impact of the policy change on hospital admissions offset by 
practice size and adjusted for seasonality. Similar linear 
models were fitter for prescriptions (Defined Daily Doses). 
The interrupted time series operators fitted both a step and a 
slope change. Generalised Additive Mixed Models were 
also fitted as a sensitivity analysis without the interrupted 
time series operators but with eight knots distributed evenly 
throughout the time series to relax the linear assumption and 
check for changes in the time series unrelated to the policy 
change. 
III. RESULTS 
Prescriptions data were available for 73.6% of the 
practices across Scotland while admissions data were 
available for 75.9%. Both the analyses of admissions and 
prescriptions identified statistically significant step and/or 
slope changes in the time trends contemporary with the 
policy change. However, the changes were of greater 
magnitude in the counterfactual than the intervention group. 
The sensitivity analysis revealed that apart from hospital 
admissions for diabetes, each of the time series demonstrated 
marked non-stationarity unrelated to the policy change. 
IV. DISCUSSION 
Administrative data permitted the design and conduct of 
a rigorous evaluation of a major policy change which would 
otherwise have been very expensive. However, limitations 
with the data meant that the evidence was not sufficient to 
demonstrate that abolishing prescription fees is an effective 
or ineffective policy in terms of reducing hospital admissions 
or socioeconomic inequalities in hospital admissions. 
The study encountered two of the common challenges of 
‘big data’ research.  Firstly, the data used were originally 
collected for financial rather than health or research 
purposes, and therefore were not optimal for the study.  
Secondly, the surfeit of data meant that the models estimated 
many statistically significant coefficients, which were not 
clinically meaningful. 
Prior to the policy change less than 13% of the 
prescriptions dispensed in Scotland were paid for by the 
patient; a smaller proportion of those would have been for 
chronic medication sensitive conditions, rather than acute 
short-term conditions. The study may have been like ‘using a 
sledgehammer to crack a nut’. 
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